Status:
COMPLETED
Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)
Lead Sponsor:
Rennes University Hospital
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
The objective of CISCO is therefore to identify prognostic biomarkers of MS activity in early-stage patients.
Eligibility Criteria
Inclusion
- Patients :
- Patients with clinically isolated syndrome (CIS) participating in the OFSEP cohort (French MS Observatory)
- At least 18 years of age
- Diagnosed with MS according to criteria 2017 at the time of their last visit.
- Non-opposition to participation in the study
- Having had at least one visit in the year following collection
- Follow-up for at least 1 year after collection.
- Having signed the OFSEP consent
Exclusion
- CIS patients with progressive MS
- Healthy volunteers :
- Inclusion Criteria:
- Age 18 years or older
- Having participated in the ABCD-SEP clinical trial promoted by the Rennes University Hospital (NCT03744351).
- Matched on age and sex to patients of interest in the OFSEP cohort
- Not having objected to participation in the study
Key Trial Info
Start Date :
February 19 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 2 2022
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04510350
Start Date
February 19 2020
End Date
March 2 2022
Last Update
March 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Rennes
Rennes, France